関連する実験動画
Updated: May 6, 2026

09:11
Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs
Published on: June 14, 2012
25.5K
粘着性のあるビジネス:分子接着剤によるCRBNの亜鉛指標的の合理化
Jonathan W Bushman1, Patrick Ryan Potts1
1Induced Proximity Platform, Amgen Research, Thousand Oaks, CA, USA.
Molecular cell
|August 22, 2025
まとめ
研究者はCRBNを標的にする分子接着剤によって分解できる 亜鉛指を持つヒトのタンパク質を特定しました この研究は 難しいタンパク質を標的とする 規則を洗練し 治療の選択肢を広げています
科学分野:
- 生物化学
- 分子生物学
- 薬物の発見
背景:
- Cereblon (CRBN) E3ユビキチンリガゼ複合体は,分子接着剤の主要な標的である.
- 亜鉛指タンパク質 (ZFP) は,大きく多様なヒトタンパク質のクラスであり,その多くは構造特性により"薬剤に難易度が高い"と考えられています.
- どのZFPがCRBN媒介による分解に敏感であるかを理解することは,新しい治療法の開発に不可欠です.
研究 の 目的:
- ヒトの亜鉛指タンパク質を 徹底的に調査する
- CRBNを標的にする分子接着剤によって効果的に分解されるZFPを特定する.
- 分子接着剤によるZFPの標的化に関する既存の規則を精製し,拡張する.
主な方法:
- CRBNベースの分子接着剤を用いたヒトZFPの高通量スクリーニング.
- タンパク質の分解を定量化するためのプロテオミック分析
- 分解の配列と構造的決定因子を特定するためのバイオ情報分析
主要な成果:
- CRBN媒介による分解に敏感なヒトZFPのサブセットを特定する.
- 分子接着剤によるZFP分解に関連する配列と構造モチーフの精製.
- CRBNベースの治療戦略の既知のZFP目標の拡張
結論:
- CRBNを標的にする分子接着剤は,ヒトの特定の亜鉛指タンパク質を効果的に分解します.
- この研究は,ZFPを標的とする分子接着剤を設計するための洗練されたガイドラインを提供します.
- これらの発見は,以前は薬効性のない標的に対する治療法の開発を進めています.
関連する概念動画
Drugs for Treatment of Constipation-Predominant IBS
1.5K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Inflammatory Bowel Disease III: Crohn's Disease
69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69

